Form D · Biotechnology
ArriVent Biopharma, Inc.
Newtown Square, PA · CIK 0001868279
Offering snapshot reported Dec 29, 2022 · SEC filing
- Reported sold
- $110M Offering amount: $145M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 16, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 29, 2022 | Initial | $109,999,989 | No comparison | 17 | SEC filing |
| Feb 14, 2022 | Amendment | $150,000,000 | $69,000,000vs Jun 23, 2021 | 10 | SEC filing |
| Jun 23, 2021 | Initial | $81,000,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-469072
Source: Form D, filed Dec 29, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carl Gordon | Director |
| James Healy | Director |
| Bahija Jallal | Director |
| Stuart Lutzker | Director |
| Cong Xu | Director |
| Zhengbin (Bing) Yao | Director, Executive |
| Jason Zhang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
18 Campus Blvd. Suite 100
Newtown Square, PA, 19073-3269
Newtown Square, PA, 19073-3269